Today: 21 May 2026
AppLovin (APP) stock slides 8% after the bell as seven-day skid stretches into 2026
2 January 2026
2 mins read

AppLovin (APP) stock slides 8% after the bell as seven-day skid stretches into 2026

NEW YORK, Jan 2, 2026, 17:24 ET — After-hours

  • AppLovin shares were last down 8.2% at $618.32 in after-hours trading, the session after the 4 p.m. close.
  • The stock has fallen for seven straight sessions since a Dec. 22 record close, according to price data.
  • Investors are watching next week’s U.S. jobs report (Jan. 9) and inflation data (Jan. 13) for clues on interest-rate cuts.

Shares of AppLovin Corp fell 8.2% on Friday and were last at $618.32 in after-hours trading — the electronic session after the 4 p.m. close — as selling pressure lingered into the first U.S. session of 2026.

The slide extended a run of declines that began after the stock’s record close on Dec. 22. The stumble has also undercut the so-called Santa Claus rally window, when markets often get a late-year lift, leaving investors to reassess high-multiple software names at the start of the year.

The broader market was steadier. The Dow and S&P 500 ended higher on Friday, while the Nasdaq finished nearly flat, helped by a rally in chip stocks, a Reuters report said.

That backdrop has not stopped scrutiny of valuation in stocks tied to artificial intelligence, or “AI plays,” a shorthand for companies seen as major beneficiaries of AI spending. Joe Mazzola, head of trading & derivatives strategist at Charles Schwab, said investors are becoming “more conscious about some of the valuations that they’re paying.” Investing.com Canada

AppLovin opened at $683.50 and traded between $688.36 and $611.06 on Friday, with about 5.6 million shares changing hands, LSEG data showed. The stock is down about 16% from its Dec. 22 record close of $733.60.

AppLovin is a marketing platform that sells software and AI tools to help businesses reach and monetize audiences, according to Reuters data. Its products include AppDiscovery, MAX, Adjust and Wurl, and it runs real-time ad auctions for app publishers.

The shares were one of 2025’s standout winners, rising more than 100% over the year, Investors.com reported. That kind of run can leave a stock vulnerable when investors start trimming positions for profits or to reduce risk.

Trefis pointed to a technical breakdown after the stock slipped below $700 on Dec. 29, a level chart watchers had treated as “support” — a price area where buyers have tended to step in. The firm said year-end profit-taking and a cooling appetite for high-valuation tech stocks intensified the move. Trefis

AppLovin’s drop also stood out versus several ad-tech peers. The Trade Desk was down about 0.8%, while Unity Software was little changed and Magnite fell about 1% in late trading, LSEG data showed.

Analysts remain divided on whether the pullback reflects stretched expectations or an entry point. Barron’s reported that Morningstar’s Mark Giarelli has argued for taking profits, while Loop Capital’s Rob Sanderson said he saw no fundamental catalyst behind the recent dip.

The next catalysts may come from the macro calendar rather than company headlines. A U.S. jobs report due Jan. 9 and consumer price data due Jan. 13 could reshape bets on Federal Reserve rate cuts, which often drive valuations for growth stocks.

AppLovin has not confirmed its next earnings date, but market calendars cluster the report in mid-February. Nasdaq lists an estimated Feb. 11 date, while Investing.com shows Feb. 18.

For now, traders are watching whether the stock holds above Friday’s $611 intraday low and whether it can reclaim the $700 area that broke late last month. The stock’s 52-week range has run from roughly $200 to $746, underscoring how quickly sentiment can swing for high-growth software names.

Stock Market Today

  • Analysts Boost Broadcom Price Targets Despite Stock Dip
    May 20, 2026, 11:22 PM EDT. Broadcom (AVGO) shares fell 6.5% to $411.07 on May 19, retreating from a record high of $439.79 on May 14. Despite this drop, several major analysts raised their price targets. Wells Fargo lifted its target to $545 from $430, TD Cowen to $500 from $405, and UBS to $490 from $475, all maintaining buy ratings. Evercore ISI's Mark Lipacis, a top-ranked analyst, raised his target to $582, citing growing demand for Broadcom's custom AI chips amid shifts in AI workloads. Risks remain from semiconductor market volatility and geopolitical tensions impacting chip deals. Broadcom's strategic moves, including its VMware acquisition and partnerships with Google and Meta for AI-focused chips, position it well in enterprise infrastructure and AI growth.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Broadcom stock today: AVGO holds gains after hours as CFO sale notice and chip rally grab attention
Previous Story

Broadcom stock today: AVGO holds gains after hours as CFO sale notice and chip rally grab attention

Western Digital stock surges nearly 9% to start 2026 — what’s driving WDC now
Next Story

Western Digital stock surges nearly 9% to start 2026 — what’s driving WDC now

Go toTop